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Abstract
Introduction: Soluble urokinase-type plasminogen activator receptor (suPAR) has been proposed as a biologic
marker of fibrinolysis and inflammation. The aim of this study was to investigate the diagnostic and prognostic
value of systemic and pulmonary levels of suPAR in burn patients with inhalation trauma who need mechanical
ventilation.
Methods: suPAR was measured in plasma and nondirected lung-lavage fluid of mechanically ventilated burn
patients with inhalation trauma. The samples were obtained on the day of inhalation trauma and on alternate days
thereafter until patients were completely weaned from the mechanical ventilator. Mechanically ventilated patients
without burns and without pulmonary disease served as controls.
Results: Systemic levels of suPAR in burn patients with inhalation trauma were not different from those in control
patients. On admission and follow up, pulmonary levels of suPAR in patients with inhalation trauma were
significantly higher compared with controls. Pulmonary levels of suPAR highly correlated with pulmonary levels of
interleukin 6, a marker of inflammation, and thrombin-antithrombin complexes, markers of coagulation, but not
plasminogen activator activity, a marker of fibrinolysis. Systemic levels of suPAR were predictive of the duration of
mechanical ventilation and length of intensive care unit (ICU) stay. Duration of mechanical ventilation and length
of ICU stay were significantly longer in burn-injury patients with systemic suPAR levels > 9.5 ng/ml.
Conclusions: Pulmonary levels of suPAR are elevated in burn patients with inhalation trauma, and they correlate
with pulmonary inflammation and coagulation. Although pulmonary levels of suPAR may have diagnostic value in
burn-injury patients, systemic levels of suPAR have prognostic value.
Introduction
Soluble urokinase plasminogen activator receptor
(suPAR) has recently been recognized as a potential bio-
logic marker of disease. suPAR derives from proteolytic
cleavage and release from cell membrane-bound uroki-
nase plasminogen activator receptor (uPAR) and has
been detected in different types of body fluids, including
blood, urine, cerebrospinal fluid, and pleural, pericardial,
and peritoneal fluid [1,2]. Numerous observational stu-
dies show systemic levels of suPAR to be increased with
various infectious and inflammatory illnesses [3-9]. In
addition, suPAR has been shown to have prognostic
value in predicting the outcome of critically ill patients
[10-13].
Inhalation trauma is a significant cause of death in
patients with burn injury [14,15] and is associated with
increased risks of pneumonia and acute respiratory dis-
tress syndrome [16,17]. Although the diagnosis of inha-
lation trauma is preferably based on fiberoptic
observations, bronchoscopy is an invasive procedure
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frequently bronchoscopy does not adequately inform on
the severity of pulmonary injury [19,20].
The aim of the present study was to investigate the
value of suPAR in the assessment of inhalation trauma
in burn patients. We recently investigated markers of
inflammation and coagulation in nondirected lung-
lavage fluids from burn patients with inhalation trauma
[21]. We showed inhalationt r a u m at ob ea s s o c i a t e d
with a proinflammatory and procoagulant shift in the
bronchoalveolar compartment, similar to that previously
shown in patients with acute lung injury [22]. As suPAR
has been proposed as a biologic marker of fibrinolysis
and inflammation, we hypothesized levels of suPAR to
be elevated in lung-lavage fluid of burn patients with
inhalation trauma and to correlate with markers of
inflammation and coagulopathy. Further, we hypothe-
sized suPAR to have a prognostic value for the duration
of mechanical ventilation in burn patients with inhala-
tion trauma. Therefore, we measured levels of suPAR in
nondirected lung-lavage fluid and plasma of burn
patients with confirmed inhalation trauma and com-
pared them with those in patients without burns or
inhalation trauma.
Materials and methods
Study design
This observational cohort study was performed in the
intensive care units (ICUs) of a regional teaching hospi-
tal specialized in care for burn patients (Rode Kruis Zie-
kenhuis-Burn Center Beverwijk, Beverwijk, The
Netherlands) and an academic center (Academic Medi-
cal Center, Amsterdam, The Netherlands).
Ethical approval
The local medical ethics committees of both hospitals
approved the study protocol, and informed consent was
obtained from patients or their legal representatives
before inclusion.
Patients
Patients included in this analysis are identical to those
enrolled in an earlier published observational study
that originally investigated pulmonary coagulation and
fibrinolysis in burn patients with inhalation trauma
[21]. The clinical diagnosis of inhalation trauma in
burn patients had to be confirmed with bronchoscopy
showing soot or infralaryngeal mucosal damage, indi-
cating exposure of the tracheobronchial tree to the
physical products of combustion. Patients with neither
burn injuries nor inhalation trauma who did not meet
the North American European Consensus Conference
(NAECC) criteria for ALI/ARDS served as control
patients.
Patients were included in the study if they were
expected to need mechanical ventilation > 72 hours.
Reasons for exclusion were participation in any inter-
ventional trials, pregnancy, (suspected) increased intra-
cranial pressure, preexisting severe chronic respiratory
disease (defined as a forced expiratory volume in 1 sec-
ond to forced vital capacity ratio < 0.64, and taking daily
medication), (suspected) pneumonia, and the use of cor-
ticosteroids or other immunosuppressive agents and
intravenously administered heparin.
Mechanical ventilation
All patients were mechanically ventilated in a volume-
controlled mode with tidal volumes of 6 ml/kg predicted
body weight. The levels of positive end-expiratory pres-
sure (PEEP) and inspired oxygen (FiO2)w e r et i t r a t e d
according to a local protocol. The ventilator was routi-
nely (at least 3 times per day) switched to the pressure-
support mode. If the pressure-support mode was toler-
ated, this mode was used for further mechanical ventila-
tion until tracheal extubation.
Tracheal extubation criteria
Attending physicians decided to remove the translaryn-
geal tube for mechanical ventilation based on general
extubation criteria (that is, responsive and cooperative,
adequate oxygenation with FiO2 ≤40%, hemodynamically
stable, no uncontrolled arrhythmia, and a rectal tem-
perature > 36.0°C) and no need for repeated surgery
during the first week. From the first week, patients were
extubated independent of whether a need for surgery
existed, even if surgery was planned for the following
day, and the first tracheal extubation was counted as the
last moment of mechanical ventilation unless a patient
needed mechanical ventilation because of continued
respiratory insufficiency.
Specimen collection and processing
Blood-sample collection followed by nondirected lung
lavage was performed on ICU admission and on alter-
nate days throughout the period of mechanical ventila-
tion. Blood samples were drawn into sterile Vacutainer
tubes containing citrate, by using an already in place
arterial catheter. Lung lavage was performed by instilling
2 0m lo fs t e r i l e0 . 9 %s a l i n ev i aas t a n d a r d5 0 - c m1 4 - F r
tracheal suction catheter, as described previously [23].
In short, the distal end of the catheter was introduced
via the endotracheal tube and advanced until significant
resistance was encountered. Immediately after instilla-
tion, over as 10-second period, fluid was aspirated
before withdrawal of the catheter. Generally, 4 to 8 ml
of fluid was recovered.
B l o o da n dl a v a g ef l u i dw e r ek e p ta t4 ° Cu n t i lp r o c e s -
sing, which was performed within 1 hour. Blood and
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Page 2 of 11lavage samples were centrifuged for 10 minutes at 4°C at
1,800 g and 800 g, respectively. The supernatants were
stored at -80°C until assays were performed.
Data collection
Demographic data, admission diagnosis, and the extent
of burn injury, calculated by using Lund-Bowder charts
and expressed as a percentage of the total body surface
area (TBSA), were collected. The lung injury score (LIS)
[24] and the oxygenation index (OI) [25] were
calculated.
Assays
suPAR was measured by using the suPARnostic kit (Viro-
Gates, Copenhagen, Denmark) according to the recom-
mendations by the manufacturer. Interleukin (IL) 6 was
measured by means of commercial enzyme-linked immu-
nosorbent assay (ELISA) kits (Sanquin, Amsterdam, The
Netherlands). Thrombin-antithrombin complex (TATc)
and plasminogen activator activity (PAA), as reported
earlier [21], were used as markers of coagulopathy.
Statistical analysis
All data are expressed as medians with their interquartile
ranges (IQRs). The nonparametric Mann-Whitney U test
was used for comparisons between groups at different
time points. Correlation between the extent of burn
injury and systemic and local levels of suPAR were
assessed with linear regression analysis of the value on
admission and the maximal value in each patient during
the complete observation period. The nonparametric
Spearman test was used for all other correlations. The
area under the receiver operating characteristics (ROC)
curve was used to calculate the discriminative ability of
suPAR. Sensitivity and specificity were calculated accord-
ing to ROC curves. The rate of freedom from mechanical
ventilation or ICU stay was analyzed according to the
Kaplan-Meier method, and the results were compared
with the log-rank test. A value of P ≤ 0.05 was considered
to be statistically significant. PASW version 18.0.0 (SPSS
Inc., Chicago, IL, USA) and Graphpad Prism version 5.01
(Graphpad software Inc., San Diego, CA, USA) were used
for statistical analyses and drawing figures.
Results
Patients
The study included 28 patients. Two burn-injury patients
were excluded because insufficient material was obtained
for analysis, resulting in 11 patients with burn injuries
and inhalation trauma and 15 control patients. In total,
96 plasma samples and corresponding lung-lavage fluid
samples were available for the present analysis. Baseline
characteristics are shown in Table 1. The study popula-
tion was predominantly men and ranged in age from 22
to 85 years. Study groups were well balanced with respect
to gender and LIS. Burn patients, however, were signifi-
cantly younger than control patients.
Systemic and pulmonary levels of suPAR
Systemic levels of suPAR were similar in burn patients
with inhalation trauma and in controls (Figure 1a). Pul-
monary levels of suPAR, however, were significantly
higher in burn patients with inhalation trauma as com-
pared with controls, both on admission and at days 3 and
5 (Figure 1b). We were unable to evaluate differences in
suPAR levels between both groups after day 5, because
13 (87%) control patients were extubated on day 7. Sys-
temic and pulmonary levels of suPAR did not correlate
Table 1 Baseline characteristics
Patients with burn injuries with inhalation trauma (n = 11) Control patients (n = 15) P value
Age (years) 38 (26-43) 74 (62-77) < 0.001
a
Male sex (%) 72.7 66.7 0.75
LIS on admission 1.38 (0.94-1.75)
b 1.25 (1.00-1.75) 0.82
Burn injuries
TBSA (%) 25 (14-48) - -
TBSA third-degree burns (%) 8 (1-39.5) - -
Admission diagnosis -
Burn injuries with inhalation trauma 11 -
Postoperative complication - 1
Neurologic - 3
Sepsis - 1
Asthma cardiale (after MI) - 1
Trauma - 2
Resuscitation after cardiac arrest - 7
Data represent median (interquartile range). Comparison between groups was done by using the Mann-Whitney U test. LIS, Lung Injury Score; MI, myocardial
infarction; TBSA, total body surface area burned.
aSignificant.
bLung Injury Score of one patient was missing.
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controls (data not shown). In addition, neither systemic
nor pulmonary levels of suPAR (on admission and their
maximal values) were associated with the extent of burn
injury or the extent of pulmonary injury, as neither of
them correlated with the percentage of TBSA burned,
the LIS, or the OI (data not shown).
Prediction of inhalation trauma
Further to investigate the predictive value of suPAR in
burn-injury patients with inhalation trauma, we
calculated the area under the receiver operating charac-
teristic curve (AUC). The AUC of systemic levels of
suPAR for predicting inhalation trauma on admission
was low: 0.61 (95% confidence interval (CI), 0.39 to 0.83]
(Figure 2a). In contrast, the AUC of pulmonary levels of
suPAR for predicting inhalation trauma on admission
was high: 0.84 (95% CI, 0.67 to 1.0; Figure 2b).
Correlations between levels of suPAR and inflammation
Systemic and pulmonary levels of IL-6 were markedly
higher in burn-injury patients with inhalation trauma
compared with control patients. Correlation analyses of
systemic levels of suPAR with systemic levels of IL-6,
and pulmonary levels of suPAR with pulmonary levels
of IL-6, were mostly significant (Figure 3).
Correlation between levels of suPAR and coagulopathy
Correlations between systemic levels of suPAR and mar-
kers of coagulopathy in burn patients were poor (data
not shown). Pulmonary levels of suPAR did correlate
with levels of TATc, a measure of coagulation. However,
pulmonary levels of suPAR did not correlate with PAA,
a measure of fibrinolysis (Figure 4).
Prognostic value of suPAR
We examined the prognostic value of maximal suPAR
levels in burn-injury patients and control patients. Pul-
monary levels of suPAR did not correlate with duration
of mechanical ventilation or ICU length of stay (LOS),
neither in the burn-injury group (Figure 5a), nor in the
control group. Systemic levels of suPAR, however, corre-
lated significantly with both duration of mechanical ven-
tilation and ICU-LOS in the burn-injury group (Figure
5b). This correlation was not found in the control
group. Of note, systemic levels of suPAR also correlated
significantly with both duration of mechanical ventila-
tion and ICU-LOS when all ICU patients were evaluated
together (P = 0.009, r = 0.50, and P = 0.01, r = 0.49,
respectively).
With a cut-off of 9.5 ng/ml, systemic suPAR was a
significant discriminator of the duration of mechanical
ventilation (AUC, 0.93 (0.73 to 1.0); sensitivity, 100%;
specificity, 80%; and ICU-LOS (AUC, 0.93 (0.78 to 1.0);
sensitivity, 100%; specificity, 80%) in the burn-injury
group).
Duration of mechanical ventilation and ICU-LOS were
significantly longer in burn-injury patients with systemic
levels of suPAR > 9.5 ng/ml (Figure 6a and 6b). The
rates of freedom from mechanical ventilation and ICU
stay were significantly higher in burn patients with
suPAR < 9.5 ng/ml (Figure 6c and 6d).
Repeated surgery during the first week might have
delayed the clinical decision to extubate burn-injury
patients. This was the case for two patients. After
control burn control burn control burn
0
5
10
15
20
25
30
(N = 15) (N = 11) (N = 15) (N = 11) (N = 4) (N = 10)
Day 1 Day 3 Day 5
A P = 0.36 P = 0.96 P = 0.14
s
u
P
A
R
 
(
n
g
/
m
L
)
control burn control burn control burn
0
5
10
15
20
25
P = 0.004 P = 0.006 P = 0.002
(N = 15) (N = 11) (N = 15) (N = 11) (N = 4) (N = 10)
Day 1 Day 3 Day 5
B
s
u
P
A
R
 
(
n
g
/
m
L
)
Figure 1 Systemic and pulmonary levels of soluble urokinase-
type plasminogen activator receptor (suPAR). (a) Box plots of
systemic levels of suPAR; systemic levels of suPAR do not
significantly differ from levels in control patients on admission and
on days 3 and 5 after admission. (b) Box plots of pulmonary levels
of suPAR; compared with those in control patients, pulmonary levels
of suPAR are significantly higher in burn-injury patients on
admission and on days 3 and 5 after admission. Boxes represent the
interquartile ranges. Outliers are excluded from the figure. N,
number of patients per group per time point. The P values indicate
statistical significance.
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considered the day of extubation), systemic suPAR
remained correlated with the duration of mechanical
ventilation (P = 0.02; r = 0.69) and remained a signifi-
cant predictor of the duration of mechanical ventilation
(AUC, 0.96 (0.86 to 1.0); P = 0.01).
Discussion
To our knowledge, this study is the first to show that
suPAR is measurable in lung-lavage fluid. On admission
as well as on days 3 and 5, pulmonary levels were con-
sistently higher in burn patients with inhalation trauma
as compared with mechanically ventilated patients who
were not exposed to fire. Notably, no significant differ-
ence was found in systemic levels of suPAR between
burn patients and controls. Pulmonary levels of suPAR
correlated with inflammation and coagulation, but not
with fibrinolysis. Although pulmonary levels of suPAR
did not have prognostic value in burn patients, systemic
levels of suPAR were predictive of the duration of
mechanical ventilation and ICU-LOS.
The observation that pulmonary levels, but not sys-
temic levels of suPAR, were significantly higher in venti-
lated patients with pulmonary pathology as compared
with ventilated controls, suggests the local production of
suPAR within the lung. It also indicates that cutaneous
burns do not significantly contribute to suPAR levels.
This is further exemplified by the finding that TBSA
percentage burned and suPAR did not correlate with
each other. Notably, it seems that suPAR does not ade-
q u a t e l yq u a n t i f yt h es e v e r i t yo fp u l m o n a r yi n j u r y ,a s
neither systemic nor pulmonary levels of suPAR corre-
lated with the LIS or the OI. It should be mentioned
that we could have failed to detect some small correla-
tions because of the small patient population.
The presence of inhalation injury is not always
obvious in burn patients, as pulmonary symptoms may
not appear until 24 hours after exposure [26,27]. An
objective confirmation of an inhalation burn, apart from
possible therapeutic reasons, is vital for the prognosis.
Currently, direct inspection of the airways through
bronchoscopy is recommended in patients clinically sus-
pected of inhalation trauma [20]. However, broncho-
scopy is an invasive procedure, which may enhance
hypoxia in patients with significant airway obstruction.
In addition, visualization of tracheobronchial tree
beyond the site of obstruction is impossible [18,28].
Another limiting factor is the availability of experienced
personnel. Nonbronchoscopic investigations could be
safer, easier, and less physiologically disrupting [29].
Furthermore, nonbronchoscopic sampling can be
repeated frequently without a significant burden for the
patient. To date, no studies have compared broncho-
scopic versus nonbronchoscopic sampling in patients
with inhalation trauma. Although bronchoscopy is the
gold standard for the diagnosis of inhalation trauma, the
present study shows that pulmonary levels of suPAR
may discriminate between patients with and without
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Figure 2 Prediction of inhalation trauma. Receiver operating characteristic (ROC) curve comparing the ability of (a) systemic and (b)
pulmonary levels of suPAR to discriminate between the presence or absence of inhalation trauma in mechanically ventilated patients by using a
cut-off value of 6.1 ng/ml. The AUC, the P value, the sensitivity, and the specificity are given in each panel.
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Page 5 of 11inhalation trauma by using a noninvasive sampling strat-
egy. A bedside test for suPAR will be available soon, giv-
ing a readout within 15 minutes. Notably, as recent
reviews suggest systemic suPAR not to be a diagnostic
marker because of lack of specificity [1,30], it is plausi-
ble that pulmonary suPAR is a general marker of pul-
monary inflammation, rather than a specific marker for
inhalation injury. This must be addressed in future stu-
dies into other lung diseases (for example, pneumonia
(hospital acquired, community acquired, or ventilator
associated) and ALI/ARDS.
It must be noted, though, that ideally we should have
compared suPAR levels in burn patients with and with-
out inhalation injury. This was not possible in our
study, because routine diagnostic bronchoscopy is not
performed in burn patients without suspected injury,
and those patients frequently do not require mechanical
ventilation.
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Figure 3 Correlations between levels of soluble urokinase-type plasminogen activator receptor (suPAR) and inflammation. Analyses of
the correlation between systemic interleukin 6 (IL-6) levels and systemic levels of suPAR in (a) burn-injury patients and (b) control patients, and
pulmonary IL-6 levels and pulmonary levels of suPAR in (c) burn-injury patients and (d) control patients. Linear correlations with 95% confidence
intervals are shown. Pearson correlation coefficients (r) and P values are given in each panel.
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systemic levels of suPAR in critically ill patients as com-
pared with those in healthy controls [2,9,10,31]. Sys-
temic levels of suPAR in these studies were comparable
with systemic levels of suPAR in our cohort of critically
ill patients. One salient finding was that systemic levels
of suPAR were not different between burn patients with
inhalation trauma and controls.
Several studies investigated the prognostic value of
suPAR in critically ill patients and found systemic levels
of suPAR to be predictive of death [9-13,32]. Although
no correlation between systemic levels of suPAR and
LOS could be found in a general cohort of ICU patients
[10], systemic suPAR has been shown to correlate with
the need for ICU admission and the need for use of
vasopressors and mechanical ventilation in critically ill
patients [12]. The present study shows suPAR to func-
tion as a prognostic marker in burn patients with inha-
lation trauma as well (that is, high systemic levels of
suPAR are predictive for a longer duration of mechani-
cal ventilation and longer ICU-LOS).
Although suPAR has proven to have value as a biolo-
g i cm a r k e ri nav a r i e t yo fp a t h o l o g i cc o n d i t i o n s ,l i t t l ei s
known about the direct biochemical and molecular
background of these observations [1]. Although uPA
plays a key role in the fibrinolytic pathway, its receptor
(uPAR) appears to have little impact on fibrin turnover
[33]. Instead, uPAR has been suggested to be involved
in the recruitment of monocytes and neutrophils
[34,35]. Inflammatory responses might be mediated by a
direct interaction between uPAR and b-integrins [36,37].
In addition, suPAR has been reported to have direct
chemotactic properties [38,39]. Our findings are consis-
tent with these studies, because we did not observe a
correlation between suPAR and fibrinolytic activity.
Moreover, the correlation between IL-6 levels and
suPAR levels in the lungs indicates that suPAR indeed
reflects an enhanced inflammatory state. Given the rela-
tion between inflammation and coagulation [40], one
could also expect to find correlations between suPAR
and coagulation. A correlation with pulmonary levels of
TATc was found in the present study.
We recently investigated pulmonary coagulopathy in
patients with inhalation trauma and found a procoagu-
lant and antifibrinolytic shift in the pulmonary compart-
ment [21]. Small trials have shown local anticoagulation
therapy to be feasible [41] and beneficial [42] in patients
with ALI, so this could possibly be an important thera-
peutic target in patients with inhalation trauma as well.
Treatment with nebulized heparin is safe and attenuates
lung injury and the progression of acute respiratory dis-
tress syndrome in pediatric burn patients with inhala-
tion trauma [43]. At present, we are planning an
international multicenter randomized trial of nebulized
heparin versus placebo in patients with inhalation
trauma. Natural biomarkers of coagulation may be use-
ful in the guidance for this kind of therapy. Presently
used markers or measures of local coagulation and fibri-
nolysis are measurable in lavage fluids by sophisticated
laboratory tests, but these are all time consuming and
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Figure 4 Correlations between levels of soluble urokinase-type plasminogen activator receptor (suPAR) and coagulopathy. Analyses of
the correlation between pulmonary levels of suPAR and parameters of (a) pulmonary coagulation and (b) fibrinolysis. Linear correlations with
95% confidence intervals are shown. Pearson correlation coefficients (r) and P values are given in each panel.
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Page 7 of 11expensive. Given the significant correlation between pul-
monary coagulation and pulmonary levels of suPAR, it
will be interesting to investigate in future studies
whether suPAR can possibly function as guide for local
anticoagulant therapy.
A limitation of this study is the sample size. We inves-
tigated only 11 burn-injury patients. Besides the small
patient population, another limitation is that at baseline,
the patients in the control group differed from the
patients with burn injuries and inhalation trauma with
regard to age. However, it is unlikely that age affected
suPAR levels. Although systemic levels of suPAR have
been reported to increase slightly with age in healthy
subjects [44], earlier studies on suPAR in critically ill
patients did not find a correlation with age [9,10,12],
possibly because it is masked by their illness. Consistent
with this, suPAR also did not correlate with age in our
study, in either burn patients or ventilated control
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Figure 5 Prognostic value of soluble urokinase-type plasminogen activator receptor (suPAR). Analyses of the correlation between
pulmonary levels of suPAR in burn-injury patients with inhalation trauma and (a) duration of mechanical ventilation and (b) length of ICU stay,
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Page 8 of 11patients. Moreover, higher levels of suPAR were found
in the younger group and not in the older group.
Conclusions
suPAR is detectable in lung-lavage fluid and is elevated
after burns with inhalation injury. Pulmonary suPAR
levels correlate with pulmonary inflammatory activity
and coagulation, but not with fibrinolysis. Pulmonary
suPAR levels may have diagnostic value in burn-injury
patients, whereas systemic suPAR levels may have prog-
nostic value.
Key messages
￿ suPAR is detectable in lung-lavage fluid;
￿ pulmonary levels of suPAR are elevated with inha-
lation injury in mechanically ventilated burn-injury
patients;
￿ measurement of pulmonary levels of suPAR on
admission may be useful for the diagnosis of inhala-
tion injury;
￿ pulmonary levels of suPAR correlate with pulmon-
a r yi n f l a m m a t o r ya c t i v i t ya n dc o a g u l a t i o n ,b u tn o t
with fibrinolysis;
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Figure 6 Prognostic value of soluble urokinase-type plasminogen activator receptor (suPAR). Box plot of (a) duration of mechanical
ventilation and (b) length of stay in the ICU of burn-injury patients with inhalation trauma. Boxes represent the interquartile ranges. N, number
of patients per group. Kaplan-Meier curves showing the rate of freedom from (c) mechanical ventilation and (d) ICU stay in burn-injury patients
with systemic suPAR < 9.5 ng/ml and > 9.5 ng/ml. P values are given in each panel.
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